Biotechnology
15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.
30 April 2026
Latest Features
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
More News
28 April 2026 Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug
28 April 2026 BioNTech’s former rival—now part of its company—is seeking to assert its mRNA portfolio against Moderna in a new suit over modifications to the highly fought-over molecule.
22 April 2026 Decision underscores a growing deference to parallel rulings and tighter control over duplicate patent challenges.
17 April 2026 A ruling that invalidated three of Teva's headache treatment patents has been thrown out, sending a long-running case back to the lower court.
16 April 2026 The Cambridge biotech is accused of infringing six patents covering technologies used to target drug-resistant cancer mutations.
10 April 2026 The 2026 panel has been chosen. With judges from Amgen, Pfizer, Eli Lilly, Takeda, Regeneron and law firms such as White & Case and Arnold & Porter, here’s who will be deciding this year’s winners.
8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox